Skip to main content Back to Top


Buprenorphine Hydrochloride Injection

Products Affected - Description

    • Buprenex injection, Indivior, 0.3 mg/mL, 1 mL ampule, 1 count, NDC 12496-0757-01 - discontinued
    • Buprenorphine injection, Pfizer, 0.3 mg/mL, 1 mL Carpuject syringe, 10 count, NDC 00409-2012-32

Reason for the Shortage

    • Pfizer has buprenorphine injection on shortage due to manufacturing delays.
    • Par had buprenorphine injection on shortage due to increased demand.

Available Products

    • Buprenex injection, Indivior, 0.3 mg/mL, 1 mL ampule, 5 count, NDC 12496-0757-05
    • Buprenorphine injection, Par Pharmaceuticals, 0.3 mg/mL, 1 mL vial, 5 count, NDC 42023-0179-05

Estimated Resupply Dates

    • Pfizer has buprenorphine 0.3 mg/mL 1 mL Carpuject syringes on back order and the company estimates a release date of August 2020.


Updated August 7, 2019 by Leslie Jensen, PharmD, Drug Information Specialist. Created April 27, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins